Exhibit 99.1 Veracyte Announces Third Quarter 2025 Financial Results Grew total revenue to $131.9 million and testing revenue to$127.8 million, representing increases of 14% and 17% year- over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 4, 2025 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. "We delivered another outstanding quarter of tes ...